Brainstorm Cell Therapeutics Inc
NASDAQ:BCLI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
PC Jeweller Ltd
NSE:PCJEWELLER
|
IN |
|
Q
|
Qliro AB
STO:QLIRO
|
SE |
|
C
|
Crompton Greaves Consumer Electricals Ltd
NSE:CROMPTON
|
IN |
P/B
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Valuation Scenarios
If P/B returns to its Industry Average (4.6), the stock would be worth $-3.09 (456% downside from current price).
| Scenario | P/B Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -1.3 | $0.87 |
0%
|
| Industry Average | 4.6 | $-3.09 |
-456%
|
| Country Average | 2.5 | $-1.7 |
-295%
|
Forward P/B
Today’s price vs future total equity
Peer Comparison
| Market Cap | P/B | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Brainstorm Cell Therapeutics Inc
NASDAQ:BCLI
|
9.6m USD | -1.3 | -0.9 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -164 720.7 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
360.1B USD | -110.1 | 86 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
188.7B USD | 21.8 | 24.5 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
168.6B USD | 7.4 | 19.8 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
111.5B USD | 6 | 28.2 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -5 465.3 | -533.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.2B USD | 2.5 | 17.6 | |
| NL |
|
argenx SE
XBRU:ARGX
|
43.8B EUR | 7 | 39.6 | |
| AU |
|
CSL Ltd
ASX:CSL
|
66.3B AUD | 2.4 | 32.1 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 18.2 | -61.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.5 |
| Median | 2.5 |
| 70th Percentile | 4.8 |
| Max | 147 580.5 |
Other Multiples
Brainstorm Cell Therapeutics Inc
Glance View
Brainstorm Cell Therapeutics, Inc. operates as a biotechnology company, which develops and commercializes adult stem cell therapeutic products. The company is headquartered in New York City, New York and currently employs 43 full-time employees. The company went IPO on 2003-05-28. The firm is focused on the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), Alzheimer's disease (AD), and other neurodegenerative diseases. NurOwn, its cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells (MSCs) to secrete high levels of neurotrophic factors (NTFs), modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. NurOwn has completed its phase III ALS and phase II PMS clinical trials. Its wholly owned subsidiary, BrainStorm Cell Therapeutics Ltd. holds the rights to commercialize its NurOwn technology. Its other subsidiaries include Advanced Cell Therapies Ltd., and two others.
